Cerecor has announced Dr Simon Pedder has been appointed to its board of directors.
"We are delighted to welcome Dr Pedder to our Board," said Dr Uli Hacksell, chairman of the board of Cerecor.
"With his experience in all stages of drug development and collaborating with the FDA on several products leading to approval, Dr Pedder is a key addition for the Company. He will provide valuable insights and strategic guidance as we continue to develop our innovative compounds."
"I am extremely pleased to welcome Dr Pedder to our Board," said Peter Greenleaf, CEO and board member.
"Simon has led and built businesses, experience that will benefit Cerecor as we continue our rapid growth through business development, commercial excellence, and efficient drug development."
"Importantly, Simon played a key role in the development of Tolcapone, the first FDA approved COMT inhibitor for Parkinson's and led the development for Northera in Droxidopa, the first FDA approved therapy to demonstrate a symptomatic benefit in patients with neurogenic orthostatic hypotension (nOH). Both are areas of focus for Cerecor."
Dr Simon Pedder currently serves as the Chief Business and Strategy Officer, Proprietary Products at Athenex, a global biopharmaceutical company dedicated to the discovery, development and commercialisation of novel therapies for treatment of cancer.
Dr Pedder stated: "I am excited about working with the accomplished team at Cerecor. I have known several of the Directors and employees for quite some time, which was instrumental in my decision. I look forward to contributing to the development of Cerecor's next generation CNS compounds that are poised for success and to the overall success of the Company."
